No. As of 2025, your doctor cannot prescribe retatrutide. It has not received FDA approval or approval from any major regulatory body worldwide. It is still in clinical trials.
That is the straight answer. But there is a lot more worth knowing here, because the research behind this drug is genuinely interesting, and there are real options available to you right now.
What Is Retatrutide and Why Is Everyone Talking About It?
Retatrutide is a triple hormone receptor agonist. It targets three receptors at once, GLP-1, GIP, and glucagon. Most weight loss drugs on the market right now only hit one or two of those targets. Semaglutide hits GLP-1. Tirzepatide hits GLP-1 and GIP. Retatrutide hits all three. regulatory body
In my experience reviewing the clinical data on these compounds, the jump in results from dual to triple agonism is not small. The Phase 2 trial published in the New England Journal of Medicine in 2023 showed participants losing up to 24.2% of their body weight over 48 weeks at the highest dose. That is more than any approved medication has produced in a comparable timeframe.
What I saw in that data was that the glucagon receptor activation appears to drive extra energy expenditure on top of the appetite suppression you get from GLP-1. That combination is why the numbers look so different from what we have seen before.
Is Retatrutide Currently Available by Prescription?
No. Eli Lilly, the company developing retatrutide, completed Phase 2 trials in 2023. Phase 3 trials are currently underway. Until those finish and the FDA reviews the full safety and efficacy data, no doctor anywhere can legally prescribe it as a standard treatment.
Compounding pharmacies cannot make it either. The compounds that compounding pharmacies have been producing, like semaglutide and tirzepatide, were only permitted because those drugs were on the FDA shortage list. Retatrutide is not approved at all, so there is no legal pathway for compounding.
If someone is offering you retatrutide outside of a clinical trial, that is a serious red flag.
Can I Ask My Doctor to Enroll Me in a Retatrutide Clinical Trial?
Yes, and this is actually worth pursuing if you are serious about it.
Phase 3 trials for retatrutide are actively recruiting. You can search for open trials at ClinicalTrials.gov by searching the term retatrutide. Eli Lilly is running multiple trials under the TRIUMPH program, covering obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis.
Your doctor can refer you, or you can apply directly through the trial listings. You will need to meet specific eligibility criteria, which typically includes a BMI over 30, or over 27 with a weight-related health condition. You cannot have certain other conditions or be on certain medications.
What I found when looking at how these trials work is that participants get the drug at no cost, receive close medical monitoring, and contribute to research that will eventually determine whether this drug reaches the public. The tradeoff is that you may be randomized to a placebo group, and the time commitment is significant.
When Might Retatrutide Become Available for Doctors to Prescribe?
The realistic estimate is 2026 to 2027, assuming Phase 3 data is strong and the FDA review moves at a normal pace.
Here is how the timeline typically works. Phase 3 trials usually run 1 to 2 years. After that, Eli Lilly submits a New Drug Application to the FDA. The FDA standard review takes about 12 months. Priority review, which the FDA can grant for drugs addressing serious conditions, cuts that to 6 months.
Given the Phase 2 results and the existing infrastructure Eli Lilly has built around tirzepatide, there is reason to think this process could move efficiently. But drug development timelines slip. Phase 3 trials can reveal safety signals that require more study. Regulatory agencies ask for additional data. I would not plan your health strategy around a specific date.
Are There Similar FDA-Approved Medications My Doctor Can Prescribe Now?
Yes. Two medications are worth knowing about in detail.
Semaglutide
Semaglutide is approved under the brand names Ozempic for type 2 diabetes and Wegovy for chronic weight management. It is a GLP-1 receptor agonist given as a weekly injection. The STEP 1 trial showed an average weight loss of 14.9% over 68 weeks. Your doctor can prescribe this now if you meet the criteria, which is a BMI of 30 or higher, or 27 or higher with a weight-related condition.
Tirzepatide
Tirzepatide is approved as Mounjaro for type 2 diabetes and Zepbound for obesity. It targets both GLP-1 and GIP receptors. The SURMOUNT-1 trial showed average weight loss of 20.9% at the highest dose over 72 weeks. That is closer to retatrutide territory than semaglutide, and it is available right now.
When I tried to understand why tirzepatide outperforms semaglutide, the GIP receptor activation seems to improve how the body responds to GLP-1 signaling, not just add a second mechanism on top. The two receptors work together in a way that amplifies the effect.
Both medications work best when combined with changes to eating patterns and physical activity. The drug reduces appetite and improves metabolic signaling. What you do with that reduced appetite determines how much of the weight loss you keep long term.
What Should I Tell My Doctor If I Am Interested in Retatrutide?
Be direct. Tell your doctor you have been reading about retatrutide, you understand it is not approved yet, and you want to know your options.
A good doctor will not dismiss that conversation. They will likely walk you through the approved GLP-1 medications, assess whether you qualify, and discuss whether a clinical trial referral makes sense for your situation.
Bring specific information to the appointment. Know your current BMI. Know your relevant health history, including blood sugar levels, blood pressure, and any cardiovascular history. Know what you have already tried. Doctors make better decisions when patients come prepared.
If your doctor is not familiar with the current GLP-1 landscape or dismisses your interest without discussion, that is useful information too. Seeking a second opinion from an endocrinologist or a doctor who specializes in metabolic health is a reasonable next step.
Three Things Most People Get Wrong About Retatrutide
- They think it is just a stronger version of Ozempic. It is not. The glucagon receptor component changes the mechanism in a meaningful way. Glucagon increases energy expenditure. GLP-1 reduces appetite. GIP improves insulin response. Hitting all three at once is a different approach, not just a higher dose of the same thing.
- They think waiting for retatrutide is a strategy. It is not. If you have a weight-related health condition right now, waiting 2 years for a drug that may or may not be approved is not a plan. Tirzepatide exists today and produces results that would have seemed impossible 5 years ago.
- They think the drug does all the work. The trial data is collected in controlled settings with dietary guidance and monitoring. In my experience looking at real-world outcomes versus trial outcomes, the gap is significant when people do not change their eating behavior alongside the medication. The drug creates a window. You still have to use it.
Can my doctor prescribe retatrutide if I have type 2 diabetes?
No. The answer is the same regardless of your diagnosis. Retatrutide is not approved for any indication. However, if you have type 2 diabetes, you have more approved options available to you right now. Both semaglutide and tirzepatide are approved for type 2 diabetes management, and both produce significant weight loss alongside blood sugar control. Your doctor can prescribe either of those today.
FAQ
Is retatrutide the same as tirzepatide?
No. Tirzepatide targets two receptors, GLP-1 and GIP. Retatrutide targets three, adding glucagon. They are made by the same company, Eli Lilly, but they are different drugs with different mechanisms and different trial results.
Can I buy retatrutide online?
No legitimate source sells retatrutide. Any website claiming to sell it is selling something unverified, mislabeled, or counterfeit. Do not buy it.
What are the side effects of retatrutide?
Based on Phase 2 trial data, the most common side effects are nausea, vomiting, diarrhea, and constipation. These are consistent with other GLP-1 class medications. The Phase 2 trial also noted increases in heart rate, which is being monitored closely in Phase 3. Full safety data will not be available until Phase 3 is complete.
Will retatrutide be covered by insurance?
Unknown. Insurance coverage for obesity medications in general is inconsistent. Coverage decisions will depend on the approved indication, the price Eli Lilly sets, and individual insurance plan policies. This is a question for after approval.
Is retatrutide better than semaglutide?
The Phase 2 data suggests stronger weight loss outcomes than semaglutide. But Phase 2 trials are not designed to directly compare drugs, and Phase 3 data may look different. What I found in the data is that the effect size is large enough to take seriously, but head-to-head comparison trials would be needed to make a definitive claim.
What to Do Right Now
If weight management is a priority for you, here is a practical path forward.
- Book an appointment with your doctor and ask specifically about GLP-1 medications. Bring your BMI and relevant health history.
- If you want to pursue a clinical trial, go to ClinicalTrials.gov and search retatrutide. Review the eligibility criteria before your appointment so you can have an informed conversation.
- Start working on the behavioral side now, not when the drug arrives. The research on GLP-1 medications consistently shows better long-term outcomes when medication is combined with structured eating habits and regular physical activity. Working with an online personal trainer can help you build that structure before or alongside any medical treatment.
The drug pipeline is genuinely exciting. But the best outcomes I have seen come from people who treat medication as one tool in a larger system, not the whole answer.
